ArticleCancer treatment communications
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.
Article in Cancer treatment communications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.Journal of cancer research and clinical oncology · 2022Article
- Constructing germline research cohorts from the discarded reads of clinical tumor sequences.Genome medicine · 2021Article
- Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non-Small-Cell Lung Cancer.JCO precision oncology · 2021Observational
- Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study.Translational oncology · 2019Article
- Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.Journal of cellular and molecular medicine · 2018Article
- Tumor biomarker testing in non-small-cell lung cancer: A decade of change.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture.Oncotarget · 2017Article
- Digenic heterozygous mutations in EYS/LRP5 in a Chinese family with retinitis pigmentosa.International journal of ophthalmology · 2017Article
- De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Lung cancer (Amsterdam, Netherlands) · 2016Article
- Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Translational lung cancer research · 2016Article
- Changing paradigm of cancer therapy: precision medicine by next-generation sequencing.Cancer biology & medicine · 2016Article
- Next-generation sequencing: advances and applications in cancer diagnosis.OncoTargets and therapy · 2016Review
- PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?Journal of the American Society of CytopathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
introductionTumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day clinical practice altered therapeutic decision-making.
methodsClinicopathologic data, tumor genotype, and clinical decisions were retrospectively compiled over 6 months following introduction of NGS assay use at our institution in 82 patient-tumor samples (7 by primary NGS, 22 by sequential SGAs followed by NGS, and 53 by SGAs).
resultsSGAs identified abnormalities in 34 samples, and all patients with advanced
conclusionsTargeted NGS can identify a significant number of therapeutically-relevant driver events in lung ACs; particularly in never or light smokers. For SC lung cancers, NGS is less likely to alter current practice. Further research into the cost effectiveness and optimal use of NGS and improved provider training in genomic oncology are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.